Enalaprilat
Vasotec (enalaprilat) is a small molecule pharmaceutical. Enalaprilat was first approved as Vasotec on 1988-02-09. It is used to treat bartter syndrome, diabetic nephropathies, edema, heart failure, and left ventricular dysfunction amongst others in the USA. The pharmaceutical is active against angiotensin-converting enzyme.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Enalaprilat
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VASOTEC | Bausch Health Companies | N-019309 DISCN | 1988-02-09 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| enalaprilat | ANDA | 2024-01-04 |
| vasotec | New Drug Application | 2018-11-12 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
164 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | 6 | 13 | 14 | 9 | 42 |
| Heart failure | D006333 | HP_0001635 | I50 | 1 | 5 | 15 | 13 | 2 | 33 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 3 | 4 | 3 | — | 10 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | 1 | 2 | 2 | 6 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 2 | 1 | 1 | 2 | 5 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 2 | 2 | 1 | — | 5 |
| Essential hypertension | D000075222 | — | I10 | 1 | 3 | — | 2 | — | 5 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | 1 | 3 | 5 |
| Dilated cardiomyopathy | D002311 | HP_0001644 | I42.0 | — | 3 | 3 | 1 | — | 5 |
| Covid-19 | D000086382 | — | U07.1 | — | — | 2 | 1 | 1 | 4 |
Show 26 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 2 | — | 3 | 5 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | 2 | 4 | — | — | 4 |
| Proteinuria | D011507 | HP_0000093 | R80 | — | — | 1 | — | 2 | 3 |
| Coronary disease | D003327 | — | — | — | 1 | 2 | — | 1 | 3 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 1 | — | 1 | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | 1 | 2 |
| Ischemic stroke | D000083242 | — | — | — | — | 1 | — | 1 | 2 |
| Neoplasms | D009369 | — | C80 | — | — | 2 | — | — | 2 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | 1 | — | — | 1 |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | 1 | — | — | 1 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral hemorrhage | D002543 | — | — | — | 2 | — | — | 2 | 4 |
| Blood pressure | D001794 | EFO_0004325 | — | — | 2 | — | — | — | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | — | 1 | — | — | — | 1 |
| Melanoma | D008545 | — | — | — | 1 | — | — | — | 1 |
| Glomerulonephritis | D005921 | HP_0000099 | N05 | — | 1 | — | — | — | 1 |
| Membranoproliferative glomerulonephritis | D015432 | — | — | — | 1 | — | — | — | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | — | — | — | 1 |
| Isolated systolic hypertension | D000092244 | — | — | — | 1 | — | — | — | 1 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Barrett esophagus | D001471 | EFO_0000280 | K22.7 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 1 | 1 |
| Lupus nephritis | D008181 | EFO_0005761 | — | — | — | — | — | 1 | 1 |
| Fabry disease | D000795 | Orphanet_324 | E75.21 | — | — | — | — | 1 | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | — | 1 | 1 |
| Unstable angina | D000789 | EFO_1000985 | I20.0 | — | — | — | — | 1 | 1 |
| Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | — | — | — | 1 | 1 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | — | — | 1 | 1 |
| Prehypertension | D058246 | — | — | — | — | — | — | 1 | 1 |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 1 | 1 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Enalaprilat |
| INN | enalaprilat |
| Description | Enalaprilat (anhydrous) is enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor and an antihypertensive agent. It is a dicarboxylic acid and a dipeptide. |
| Classification | Small molecule |
| Drug class | narcotic agonists/antagonists (normorphine type); antihypertensives (ACE inhibitors): antihypertensives (ACE inhibitors), diacid analogs |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 76420-72-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL577 |
| ChEBI ID | 4786 |
| PubChem CID | — |
| DrugBank | DB00584 |
| UNII ID | Q508Q118JM (ChemIDplus, GSRS) |
Target
Agency Approved
ACE
ACE
Organism
Homo sapiens
Gene name
ACE
Gene synonyms
DCP, DCP1
NCBI Gene ID
Protein name
angiotensin-converting enzyme
Protein synonyms
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1, carboxycathepsin, CD143, CD143 antigen, dipeptidyl carboxypeptidase 1, Dipeptidyl carboxypeptidase I, Kininase II, peptidase P
Uniprot ID
Mouse ortholog
Ace (11421)
angiotensin-converting enzyme (P09470)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,612 documents
View more details
Safety
Black-box Warning
Black-box warning for: Enalaprilat, Vasotec
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
720 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use